Port-A-Cath infection causes inhibitor recurrence after initial successful ITI

Haemophilia

Volumn 19, Issue 3, 2013, Pages

  Grangl, G ^a   Gallistl, S ^a   Leschnik, B ^a   Muntean, W ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; BLEEDING TENDENCY; CASE REPORT; CATHETER INFECTION; CHILD; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE DUPLICATION; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LETTER; LOW DRUG DOSE; MALE; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SOFT TISSUE BLEEDING; TREATMENT OUTCOME;

BACTERIAL INFECTIONS; BLOOD COAGULATION FACTOR INHIBITORS; CHILD, PRESCHOOL; ESCHERICHIA COLI; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; MALE; PANTOEA; RECOMBINANT PROTEINS; RECURRENCE; VASCULAR ACCESS DEVICES; VON WILLEBRAND FACTOR;

EID: 84876813519     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12103     Document Type: Letter

References (7)

1. Astermark J, Altisent C, Batorova A et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16: 747-66.
2. Astermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012; 18(Suppl. 4): 38-42.
3. Pfistershammer K, Stockl J, Siekmann J, Turecek PL, Schwarz HP, Reipert BM. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006; 96: 309-16.
4. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16: 256-62.
5. Giangrande PL, Wilde JT, Madan B et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009; 15: 501-8.
6. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
7. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279-89.